Drug developed at Pitt proves effective against antibiotic-resistant 'superbugs'
http://www.eurekalert.org/pub_releases/2014-12/uops-dda120914.php[font face=Serif]PUBLIC RELEASE DATE:
10-Dec-2014
Contact: Allison Hydzik
hydzikam@upmc.edu
412-647-9975
University of Pittsburgh Schools of the Health Sciences
@UPMCnews
[font size=5]Drug developed at Pitt proves effective against antibiotic-resistant 'superbugs'[/font]
[font size=3]PITTSBURGH, Dec. 9, 2014 - A treatment pioneered at the University of Pittsburgh Center for Vaccine Research (CVR) is far more effective than traditional antibiotics at inhibiting the growth of drug-resistant bacteria, including so-called "superbugs" resistant to almost all existing antibiotics, which plague hospitals and nursing homes.
The findings, announced online in the journal
Antimicrobial Agents and Chemotherapy and funded by the National Institutes of Health, provide a needed boost to the field of antibiotic development, which has been limited in the last four decades and outpaced by the rise of drug-resistant bacterial strains.
The team tested the two leading eCAPs against a natural antimicrobial peptide (LL37) and a standard antibiotic (colistin), the latter being used as a last-resort antibiotic against multidrug resistant bacterial infections. The scientists performed the tests in a laboratory setting using 100 different bacterial strains isolated from the lungs of pediatric cystic fibrosis patients of Seattle Children's Hospital and 42 bacterial strains isolated from hospitalized adult patients at UPMC.
The natural human antimicrobial peptide LL37 and the colistin drug each inhibited growth of about 50 percent of the clinical isolates, indicating a high level of bacterial resistance to these drugs. In marked contrast, the two eCAPS inhibited growth in about 90 percent of the test bacterial strains.
[/font][/font]